Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Isobutyryl-CoA dehydrogenase, mitochondrial (encoded by the ACAD8 gene), is an enzyme of the acyl-CoA dehydrogenase family that catalyzes the dehydrogenation of isobutyryl-CoA in the catabolic pathway of the branched-chain amino acid valine[1][2][3][4]. The protein is localized in mitochondria and plays a central role in intermediary metabolism—specifically in converting isobutyryl-CoA to methacryloyl-CoA at the third step of valine breakdown. Mutations in the ACAD8 gene cause isobutyryl-CoA dehydrogenase deficiency, a rare autosomal recessive disorder often detected by elevated C4-acylcarnitine in newborn blood screening. The clinical phenotype is highly variable: most individuals show no symptoms, but some exhibit mild growth/developmental delay, hepatic dysfunction, cold intolerance, or in rare cases, cardiomyopathy. ACAD8 deficiency is typically managed by metabolic monitoring and, if symptomatic, dietary intervention[1][2][3][4].
Not applicable (no known drugs targeting ACAD8 directly). - Enzyme deficiency: therapeutic approaches may involve dietary management and monitoring, not targeted drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Isobutyryl-CoA dehydrogenase, mitochondrial (ACAD8).